Literature DB >> 11445855

The skeletal metastatic complications of renal cell carcinoma.

J Zekri1, N Ahmed, R E Coleman, B W Hancock.   

Abstract

Of the 103 patients with advanced renal cell carcinoma 31 (30%) developed symptomatic radiologically confirmed skeletal metastases. These were typically lytic, predominantly affecting the axial skeleton and associated with considerable skeletal morbidity. Solitary bone lesions occurred in 14 (45%) of patients. The median survival of patients with bone metastases was 12 months. Hypercalcaemia was common in patients both with (29%) and without (44%) bone metastases. The number and rate of skeletal related events was similar to that seen from bone metastases from breast cancer. It would therefore be appropriate to evaluate the effectiveness of bisphosphonate treatment for reducing skeletal morbidity in advanced renal cell cancer with bone metastases.

Entities:  

Mesh:

Year:  2001        PMID: 11445855     DOI: 10.3892/ijo.19.2.379

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  57 in total

1.  Pilot trial of bone-targeted therapy combining zoledronate with fluvastatin or atorvastatin for patients with metastatic renal cell carcinoma.

Authors:  George E Manoukian; Nizar M Tannir; Eric Jonasch; Wei Qiao; Tamara M Haygood; Shi-Ming Tu
Journal:  Clin Genitourin Cancer       Date:  2011-10-01       Impact factor: 2.872

2.  Bone metastases affect prognosis but not effectiveness of third-line targeted therapies in patients with metastatic renal cell carcinoma.

Authors:  Roberto Iacovelli; Daniele Santini; Mimma Rizzo; Alessandra Felici; Matteo Santoni; Elena Verzoni; Cristina Masini; Francesco Massari; Nicola Calvani; Alessandra Mosca; Giuseppe Procopio
Journal:  Can Urol Assoc J       Date:  2015 Jul-Aug       Impact factor: 1.862

3.  Radiotherapy combined with zoledronate can reduce skeletal-related events in renal cell carcinoma patients with bone metastasis.

Authors:  Seiichi Hosaka; Hirohisa Katagiri; Masashi Niwakawa; Hideyuki Harada; Junji Wasa; Hideki Murata; Mitsuru Takahashi
Journal:  Int J Clin Oncol       Date:  2018-06-29       Impact factor: 3.402

4.  Characterization of a new renal cell carcinoma bone metastasis mouse model.

Authors:  Anne Strube; Elizaveta Stepina; Dominik Mumberg; Arne Scholz; Peter Hauff; Sanna-Maria Käkönen
Journal:  Clin Exp Metastasis       Date:  2010-05-05       Impact factor: 5.150

5.  A moth-eaten radius.

Authors:  Faisal Shehzaad Khan; Adrian B Walker; Joseph M Pappachan
Journal:  BMJ Case Rep       Date:  2014-02-03

6.  Antiresorptive agent-related osteonecrosis of the jaw (ARONJ) in urological malignancies: a multi-center retrospective study.

Authors:  Yasuyuki Sakai; Tetsuya Shindo; Shunsuke Sato; Atsushi Takahashi; Yasuharu Kunishima; Ryuichi Kato; Naoki Itoh; Manabu Okada; Hitoshi Tachiki; Keisuke Taguchi; Akio Takayanagi; Hiroshi Hotta; Hiroki Horita; Masanori Matsukawa; Masahiro Matsuki; Koyo Nishiyama; Akihiro Miyazaki; Kohei Hashimoto; Toshiaki Tanaka; Naoya Masumori
Journal:  J Bone Miner Metab       Date:  2021-03-11       Impact factor: 2.626

Review 7.  Invasion and metastasis of renal cell carcinoma.

Authors:  Shuji Mikami; Mototsugu Oya; Ryuichi Mizuno; Takeo Kosaka; Ken-ichi Katsube; Yasunori Okada
Journal:  Med Mol Morphol       Date:  2013-11-09       Impact factor: 2.309

8.  Elevated plasma osteopontin as marker for distant metastases and poor survival in patients with renal cell carcinoma.

Authors:  Azizbek Ramankulov; Michael Lein; Glen Kristiansen; Hellmuth-A Meyer; Stefan A Loening; Klaus Jung
Journal:  J Cancer Res Clin Oncol       Date:  2007-05-04       Impact factor: 4.553

Review 9.  Zoledronic acid in genitourinary cancer.

Authors:  M A Climent; U Anido; M J Méndez-Vidal; J Puente
Journal:  Clin Transl Oncol       Date:  2013-04-25       Impact factor: 3.405

10.  Difficulty in diagnosing the pathological nature of an acute fracture of the clavicle: a case report.

Authors:  Sheraz S Malik; Saiqah Azad; Shahbaz Malik; Caroline B Hing
Journal:  J Orthop Surg Res       Date:  2009-06-25       Impact factor: 2.359

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.